Rapamycin-mediated mTOR inhibition attenuates survivin and sensitizes glioblastoma cells to radiation therapy

Acta Biochimica et Biophysica Sinica

Volumn 43, Issue 4, 2011, Pages 292-300

  Anandharaj, Arunkumar ^a   Cinghu, Senthilkumar ^a   Park, Woo Yoon ^a  

^a Chungbuk National University College of Medicine   (South Korea)

Author keywords

glioblastoma; mTOR; radiation; rapamycin; survivin

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; BIRC5 PROTEIN, HUMAN; CDKN1A PROTEIN, HUMAN; CDKN1B PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; H2AFX PROTEIN, HUMAN; HISTONE; INHIBITOR OF APOPTOSIS PROTEIN; MTOR PROTEIN, HUMAN; PROTEIN KINASE B; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE;

APOPTOSIS; ARTICLE; CELL CYCLE; CELL CYCLE G1 PHASE; CELL SURVIVAL; DRUG ANTAGONISM; DRUG EFFECT; FLOW CYTOMETRY; GLIOBLASTOMA; HUMAN; METABOLISM; PATHOLOGY; PHOSPHORYLATION; RADIATION EXPOSURE; SIGNAL TRANSDUCTION; TIME; TUMOR CELL LINE; WESTERN BLOTTING;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; FLOW CYTOMETRY; G1 PHASE; GLIOBLASTOMA; HISTONES; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; SIROLIMUS; TIME FACTORS; TOR SERINE-THREONINE KINASES;

MAMMALIA;

EID: 79953217107     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1093/abbs/gmr012     Document Type: Article

References (43)

1. Nave BT, Ouwens M, Withers DJ, Alessi DR and Shepherd PR. Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. Biochem J 1999, 344 (Pt 2): 427-431. (Pubitemid 30011599)
2. Aoki M, Blazek E and Vogt PK. A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt. Proc Natl Acad Sci USA 2001, 98: 136-141. (Pubitemid 32095876)
3. Sarbassov DD, Guertin DA, Ali SM and Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005, 307: 1098-1101. (Pubitemid 40262113)
4. Guertin DA and Sabatini DM. An expanding role for mTOR in cancer. Trends Mol Med 2005, 11: 353-361. (Pubitemid 41080576)
5. Lu Y, Wang H and Mills GB. Targeting PI3K-AKT pathway for cancer therapy. Rev Clin Exp Hematol 2003, 7: 205-228. (Pubitemid 37466220)
6. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF and Markhard AL, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006, 22: 159-168.
7. Nguyen M, Huan-Tu G, Gonzalez-Edick M, Rivera VM, Clackson T, Jooss KU and Harding TC. Rapamycin-regulated control of antiangiogenic tumor therapy following rAAV-mediated gene transfer. Mol Ther 2007, 15: 912-920. (Pubitemid 46621649)
8. Neshat MS, Mellinghoff IK, Tran C, Stiles B, Thomas G, Petersen R and Frost P, et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA 2001, 98: 10314-10319. (Pubitemid 32803017)
9. Podsypanina K, Lee RT, Politis C, Hennessy I, Crane A, Puc J and Neshat M, et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/-mice. Proc Natl Acad Sci USA 2001, 98: 10320-10325. (Pubitemid 32803018)
10. Thomas GV, Tran C, Mellinghoff IK, Welsbie DS, Chan E, Fueger B and Czernin J, et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 2006, 12: 122-127. (Pubitemid 43050086)
11. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI and Puc J, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997, 275: 1943-1947. (Pubitemid 27148818)
12. Albert JM, Kim KW, Cao C and Lu B. Targeting the Akt/mammalian target of rapamycin pathway for radiosensitization of breast cancer. Mol Cancer Ther 2006, 5: 1183-1189. (Pubitemid 43881310)
13. Eshleman JS, Carlson BL, Mladek AC, Kastner BD, Shide KL and Sarkaria JN. Inhibition of the mammalian target of rapamycin sensitizes U87 xeno-grafts to fractionated radiation therapy. Cancer Res 2002, 62: 7291-7297. (Pubitemid 36025252)
14. Chakravarti A, Noll E, Black PM, Finkelstein DF, Finkelstein DM, Dyson NJ and Loeffler JS. Quantitatively determined survivin expression levels are of prognostic value in human gliomas. J Clin Oncol 2002, 20: 1063-1068. (Pubitemid 34141851)
15. Kajiwara Y, Yamasaki F, Hama S, Yahara K, Yoshioka H, Sugiyama K and Arita K, et al. Expression of survivin in astrocytic tumors: correlation with malignant grade and prognosis. Cancer 2003, 97: 1077-1083. (Pubitemid 36173161)
16. Katoh M, Wilmotte R, Belkouch MC, de Tribolet N, Pizzolato G and Dietrich PY. Survivin in brain tumors: an attractive target for immunotherapy. J Neurooncol 2003, 64: 71-76. (Pubitemid 36992462)
17. Sasaki T, Lopes MB, Hankins GR and Helm GA. Expression of survivin, an inhibitor of apoptosis protein, in tumors of the nervous system. Acta Neuropathol 2002, 104: 105-109. (Pubitemid 36075365)
18. Wullschleger S, Loewith R and Hall MN. TOR signaling in growth and metabolism. Cell 2006, 124: 471-484. (Pubitemid 43199434)
19. Altieri DC. Targeted therapy by disabling crossroad signaling networks: the survivin paradigm. Mol Cancer Ther 2006, 5: 478-482.
20. Amaravadi R and Thompson CB. The survival kinases Akt and Pim as potential pharmacological targets. J Clin Invest 2005, 115: 2618-2624. (Pubitemid 41434384)
21. Vaira V, Lee CW, Goel HL, Bosari S, Languino LR and Altieri DC. Regulation of survivin expression by IGF-1/mTOR signaling. Oncogene 2007, 26: 2678-2684. (Pubitemid 46663841)
22. Salvesen GS and Duckett CS. IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol 2002, 3: 401-410. (Pubitemid 34685698)
23. Holcik M, Yeh C, Korneluk RG and Chow T. Translational upregulation of X-linked inhibitor of apoptosis (XIAP) increases resistance to radiation induced cell death. Oncogene 2000, 19: 4174-4177.
24. Hwang HS, Davis TW, Houghton JA and Kinsella TJ. Radiosensitivity of thymidylate synthase-deficient human tumor cells is affected by progression through the G1 restriction point into S-phase: implications for fluoropyrimidine radiosensitization. Cancer Res 2000, 60: 92-100. (Pubitemid 30058737)
25. Harper JW, Adami GR, Wei N, Keyomarsi K and Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993, 75: 805-816. (Pubitemid 23346377)
26. Lukas J, Pagano M, Staskova Z, Draetta G and Bartek J. Cyclin D1 protein oscillates and is essential for cell cycle progression in human tumour cell lines. Oncogene 1994, 9: 707-718.
27. Fu M, Wang C, Li Z, Sakamaki T and Pestell RG. Minireview: cyclin D1: normal and abnormal functions. Endocrinology 2004, 145: 5439-5447. (Pubitemid 39564581)
28. Cuevas P, Diaz-Gonzalez D and Dujovny M. Antiproliferative action of neomycin is associated with inhibition of cyclin D1 activation in glioma cells. Neurol Res 2003, 25: 691-693. (Pubitemid 37266689)
29. Buschges R, Weber RG, Actor B, Lichter P, Collins VP and Reifenberger G. Amplification and expression of cyclin D genes (CCND1, CCND2 and CCND3) in human malignant gliomas. Brain Pathol 1999, 9: 435-442; discussion 432-433.
30. Holland EC. Animal models of cell cycle dysregulation and the pathogenesis of gliomas. J Neurooncol 2001, 51: 265-276. (Pubitemid 32479299)
31. Weiss RH. p21Waf1/Cip1 as a therapeutic target in breast and other cancers. Cancer Cell 2003, 4: 425-429. (Pubitemid 38050039)
32. Jackson RJ, Adnane J, Coppola D, Cantor A, Sebti SM and Pledger WJ. Loss of the cell cycle inhibitors p21(Cip1) and p27(Kip1) enhances tumorigenesis in knockout mouse models. Oncogene 2002, 21: 8486-8497. (Pubitemid 36054889)
33. Komata T, Kanzawa T, Takeuchi H, Germano IM, Schreiber M, Kondo Y and Kondo S. Antitumour effect of cyclin-dependent kinase inhibitors (p16(INK4A), p18(INK4C), p19(INK4D), p21(WAF1/CIP1) and p27(KIP1))on malignant glioma cells. Br J Cancer 2003, 88: 1277-1280. (Pubitemid 36606346)
34. Kondo S, Barna BP, Kondo Y, Tanaka Y, Casey G, Liu J and Morimura T, et al. WAF1/CIP1 increases the susceptibility of p53 non-functional malignant glioma cells to cisplatin-induced apoptosis. Oncogene 1996, 13: 1279-1285. (Pubitemid 26343581)
35. Tanaka K, Sasayama T, Mizukawa K, Kawamura A, Kondoh T, Hosoda K and Fujiwara T, et al. Specific mTOR inhibitor rapamycin enhances cytotoxicity induced by alkylating agent 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2- chloroethyl)-3-nitrosourea (ACNU) in human U251 malignant glioma cells. J Neurooncol 2007, 84: 233-244.
36. Janumyan Y, Cui Q, Yan L, Sansam CG, Valentin M and Yang E. G0 function of BCL2 and BCL-xL requires BAX, BAK, and p27 phosphorylation by Mirk, revealing a novel role of BAX and BAK in quiescence regulation. J Biol Chem 2008, 283: 34108-34120.
37. Choi BH, Feng L and Yoon HS. FKBP38 protects Bcl-2 from caspase-dependent degradation. J Biol Chem 2010, 285: 9770-9779.
38. Shirane M and Nakayama KI. Inherent calcineurin inhibitor FKBP38 targets Bcl-2 to mitochondria and inhibits apoptosis. Nat Cell Biol 2003, 5: 28-37. (Pubitemid 36054326)
39. Fujieda S, Inuzuka M, Tanaka N, Sunaga H, Fan GK, Ito T and Sugimoto C, et al. Expression of p27 is associated with Bax expression and spontaneous apoptosis in oral and oropharyngeal carcinoma. Int J Cancer 1999, 84: 315-320. (Pubitemid 29256761)
40. Rogakou EP, Pilch DR, Orr AH, Ivanova VS and Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 1998, 273: 5858-5868. (Pubitemid 28124064)
41. Taneja N, Davis M, Choy JS, Beckett MA, Singh R, Kron SJ and Weichselbaum RR. Histone H2AX phosphorylation as a predictor of radio-sensitivity and target for radiotherapy. J Biol Chem 2004, 279: 2273-2280. (Pubitemid 38084500)
42. Steger DJ and Workman JL. Transcriptional analysis of purified histone acetyltransferase complexes. Methods 1999, 19: 410-416. (Pubitemid 30028600)
43. Liu Y, Tseng M, Perdreau SA, Rossi F, Antonescu C, Besmer P and Fletcher JA, et al. Histone H2AX is a mediator of gastrointestinal stromal tumor cell apoptosis following treatment with imatinib mesylate. Cancer Res 2007, 67: 2685-2692. (Pubitemid 46548956)